CoChat

Cell type-specific potential pathogenic genes and functional pathways in Alzheimer’s Disease

Open access
Wang, Xiao-Lan, Li, Lianjian · 2021 · BMC Neurology
Cited by 46

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Background: Alzheimer's disease (AD) is a pervasive age-related and highly heritable neurodegenerative disorder but has no effective therapy. The complex cellular microenvironment in the AD brain impedes our understanding of pathogenesis. Thus, a comprehensive investigation of cell type-specific responses in AD is crucial to provide precise molecular and cellular targets for therapeutic development. Methods: Here, we integrated analyzed 4,441 differentially expressed genes (DEGs) that were identified from 263,370 single-cells in cortex samples by single-nucleus RNA sequencing (snRNA-seq) between 42 AD-pathology subjects and 39 normal controls within 3 studies. DEGs were analyzed in microglia, astrocytes, oligodendrocytes, excitatory neurons, inhibitory neurons, and endothelial cells, respectively. In each cell type, we identified both common DEGs which were observed in all 3 studies, and overlapping DEGs which have been seen in at least 2 studies. Firstly, we showed the common DEGs expression and explained the biological functions by comparing with existing literature or multil-omics signaling pathways knowledgebase. We then determined the significant modules and hub genes, and explored the biological processes using the overlapping DEGs. Finally, we identified the common and distinct dysregulated pathways using overall DEGs and overlapping DEGs in a cell type-specific manner. Results: Up-regulated LINGO1 has been seen in both oligodendrocytes and excitatory neurons across 3 studies. Interestingly, genes enriched in the mitochondrial module were up-regulated across all cell types, which indicates mitochondrial dysfunction in the AD brain. The estrogen signaling pathway seems to be the most common pathway that is disrupted in AD. Conclusion: Together, these analyses provide detailed information of cell type-specific and overall transcriptional changes and pathways underlying the human AD-pathology. These findings may provide important insights for drug development to tackle this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12883-021-02407-1

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 63

  1. Katzman R, Saitoh T. Advances in Alzheimer's disease. FASEB J. 1991;5:278. · DOI · Paper page
  2. Mattson MP. Pathways towards and away from Alzheimer's disease (vol 430, pg 631, 2004). Nature. 2004;431:107. https://doi.org/10.1038/nature02940. · doi:10.1038/nature02940
  3. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388. https://doi.org/10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  4. Parodi-Rullan R, Sone JY, Fossati S. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease. J Alzheimers Dis. 2019;72:1019. https://doi.org/10.3233/Jad-190357. · DOI · Paper page
  5. Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Disease. 2018;9:Artn 120. https://doi.org/10.1038/S41419-017-0153-X · DOI · Paper page
  6. Laurent C, Dorothee G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2017;140:184. https://doi.org/10.1093/brain/aww270. · DOI · Paper page
  7. Fu WY, Wang XJ, Ip NY. Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. ACS Chem Nerosci. 2019;10:872. https://doi.org/10.1021/acschemneuro.8b00402. · DOI · Paper page
  8. Fakhoury M. Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy. Curr Neuropharmacol. 2018;16:508. https://doi.org/10.2174/1570159x15666170720095240. · DOI · Paper page
  9. Arranz AM, De Strooper B. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18:406. https://doi.org/10.1016/S1474-4422(18)30490-3. · DOI · Paper page
  10. Ghiso J, Fossati S, Rostagno A. Amyloidosis Associated with Cerebral Amyloid Angiopathy: Cell Signaling Pathways Elicited in Cerebral Endothelial Cells. J Alzheimers Dis. 2014;42:S167. https://doi.org/10.3233/Jad-140027. · DOI
  11. Keable A, Fenna K, Yuen HM, Johnston DA, Smyth NR, Smith C, et al. Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. BBA-Mol Basis Dis. 2016;1862:1037. https://doi.org/10.1016/j.bbadis.2015.08.024. · DOI · Paper page
  12. He Z, Han D, Efimova O, Guijarro P, Yu Q, Oleksiak A, et al. Comprehensive transcriptome analysis of neocortical layers in humans, chimpanzees and macaques. Nat Neurosci. 2017;20:886. https://doi.org/10.1038/nn.4548nn.4548. · doi:10.1038/nn.4548nn.4548
  13. Xia JG, Benner MJ, Hancock REW. NetworkAnalyst - integrative approaches for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014;42:W167. https://doi.org/10.1093/nar/gku443. · DOI · Paper page
  14. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:Artn 2. https://doi.org/10.1186/1471-2105-4-2 · DOI · Paper page
  15. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. Bmc Syst Biol. 2014;8:Artn S11. https://doi.org/10.1186/1752-0509-8-S4-S11 · DOI · Paper page
  16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498. https://doi.org/10.1101/gr.1239303. · DOI · Paper page
  17. Becnel LB, Ochsner SA, Darlington YF, McOwiti A, Kankanamge WH, Dehart M, et al. Discovering relationships between nuclear receptor signaling pathways, genes, and tissues in Transcriptomine. Science Signaling. 2017;10:ARTN eaah6275. https://doi.org/10.1126/scisignal.aah6275 · DOI
  18. Ochsner SA, Abraham D, Martin K, Ding W, McOwiti A, Kankanamge W, et al. The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019; 6:Artn 252. doi: https://doi.org/10.1038/S41597-019-0193-4 · DOI · Paper page
  19. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44. https://doi.org/10.1038/nprot.2008.211. · DOI · Paper page
  20. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109. https://doi.org/10.1093/nar/gkr988. · DOI · Paper page
  21. Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, Urushidani T, et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 2015;43:D921. https://doi.org/10.1093/nar/gku955. · DOI · Paper page
  22. Realegeno S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al. S100A12 Is Part of the Antimicrobial Network against Mycobacterium leprae in Human Macrophages. Plos Pathog. 2016;12:ARTN e1005705. https://doi.org/10.1371/journal.ppat.1005705 · DOI · Paper page
  23. Lorenzetto E, Moratti E, Vezzalini M, Harroch S, Sorio C, Buffelli M. Distribution of different isoforms of receptor protein tyrosine phosphatase gamma (Ptprg-RPTP gamma) in adult mouse brain: upregulation during neuroinflammation. Brain Struct Funct. 2014;219:875. https://doi.org/10.1007/s00429-013-0541-7. · DOI
  24. Naciff JM, Khambatta ZS, Reichling TD, Carr GJ, Tiesman JP, Singleton DW, et al. The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010;270:137. https://doi.org/10.1016/j.tox.2010.02.008. · DOI
  25. Gonit M, Zhang JA, Salazar MD, Cui HJ, Shatnawi A, Trumbly R, et al. Hormone Depletion-Insensitivity of Prostate Cancer Cells Is Supported by the AR Without Binding to Classical Response Elements. Mol Endocrinol. 2011;25:621. https://doi.org/10.1210/me.2010-0409. · DOI
  26. Zhou Q, Zhao F, Lv ZP, Zheng CG, Zheng WD, Sun L, et al. Association between APOC1 Polymorphism and Alzheimer's Disease: A Case-Control Study and Meta-Analysis. PLoS One. 2014; 9:ARTN e87017. doi: https://doi.org/10.1371/journal.pone.0087017 · DOI · Paper page
  27. Tramutola A, Di Domenico F, Barone E, Perluigi M, Butterfield DA. It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxid Med Cell Longev. 2016;2016:Artn 2756068. https://doi.org/10.1155/2016/2756068 · DOI · Paper page
  28. Hegde AN, Smith SG, Duke LM, Pourquoi A, Vaz S. Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer's Disease. Front Aging Neurosci. 2019; 11:Artn 324. https://doi.org/10.3389/Fnagi.2019.00324 · DOI · Paper page
  29. An H, Harper JW. Ribosome Abundance Control Via the Ubiquitin-Proteasome System and Autophagy. J Mol Biol. 2020;432:170. https://doi.org/10.1016/j.jmb.2019.06.001. · DOI · Paper page
  30. Sung MK, Porras-Yakushi TR, Reitsma JM, Huber FM, Sweredoski MJ, Hoelz A, et al. A conserved quality-control pathway that mediates degradation of unassembled ribosomal proteins. Elife. 2016; 5:ARTN e19105. https://doi.org/10.7554/eLife.19105 · DOI · Paper page
  31. Nelson PT, Katsumata Y, Nho K, Artiushin SC, Jicha GA, Wang WX, et al. Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging. Acta Neuropathol. 2016;132:841. https://doi.org/10.1007/s00401-016-1641-2. · DOI
  32. Hoekstra MMB, Emmenegger Y, Hubbard J, Franken P. Cold-inducible RNA-binding protein (CIRBP) adjusts clock-gene expression and REM-sleep recovery following sleep deprivation. Elife. 2019;8:ARTN e43400. https://doi.org/10.7554/eLife.43400 · DOI
  33. Eisele SC, Gill CM, Shankar GM, Brastianos PK. PLEKHA5: A Key to Unlock the Blood-Brain Barrier? Clin Cancer Res. 2015;21:1978. https://doi.org/10.1158/1078-0432.CCR-14-2604. · DOI
  34. Cui P, Su JC, Li QM, Xu GM, Zhu NX. LncRNA RHPN1-AS1 Targeting miR-625/REG3A Promotes Cell Proliferation And Invasion Of Glioma Cells. Oncotargets Ther. 2019;12:7911. https://doi.org/10.2147/Ott.S209563. · DOI
  35. Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K. Brain site-specific proteome changes in aging-related dementia. Experimental Mol Med. 2013;45:ARTN e39. https://doi.org/10.1038/emm.2013.76 · DOI · Paper page
  36. Kim JH, Franck J, Kang T, Heinsen H, Ravid R, Ferrer I, et al. Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease. Scientific Reports. 2015;5:Artn 11138. https://doi.org/10.1038/Srep11138 · DOI · Paper page
  37. Shigemizu D, Akiyama S, Asanomi Y, Boroevich KA, Sharma A, Tsunoda T, et al. Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data. Communications Biology. 2019;2:ARTN 77. https://doi.org/10.1038/s42003-019-0324-7 · DOI · Paper page
  38. Kuhn A, Kumar A, Beilina A, Dillman A, Cookson MR, Singleton AB. Cell population-specific expression analysis of human cerebellum. BMC Genomics. 2012;13:Artn 610. https://doi.org/10.1186/1471-2164-13-610 · DOI · Paper page
  39. Patel H, Hodges AK, Curtis C, Lee SH, Troakes C, Dobson RJB, et al. Transcriptomic analysis of probable asymptomatic and symptomatic alzheimer brains. Brain Behav Immun. 2019;80:644. https://doi.org/10.1016/j.bbi.2019.05.009. · DOI · Paper page
  40. Esposito M, Sherr GL. Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. Front Neurosci-Switz. 2019;13:Artn 476. https://doi.org/10.3389/Fnins.2019.00476 · DOI · Paper page
  41. Bassani S, Cingolani LA, Valnegri P, Folci A, Zapata J, Gianfelice A, et al. The X-Linked Intellectual Disability Protein TSPAN7 Regulates Excitatory Synapse Development and AMPAR Trafficking. Neuron. 2012;73:1143. https://doi.org/10.1016/j.neuron.2012.01.021. · DOI · Paper page
  42. Ohrfelt A, Brinkmalm A, Dumurgier J, Zetterberg H, Bouaziz-Amar E, Hugon J, et al. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience. 2019;420:136. https://doi.org/10.1016/j.neuroscience.2018.11.038. · DOI · Paper page
  43. Maesako M, Zoltowska KM, Berezovska O. Synapsin 1 promotes A beta generation via BACE1 modulation. PLoS One. 2019;14:ARTN e0226368. https://doi.org/10.1371/journal.pone.0226368 · DOI
  44. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transmission. 1996;103:603. https://doi.org/10.1007/Bf01273157 · DOI · Paper page
  45. Plagman A, Hoscheidt S, McLimans KE, Klinedinst B, Pappas C, Anantharam V, et al. Cholecystokinin and Alzheimer's disease: a biomarker of metabolic function, neural integrity, and cognitive performance. Neurobiol Aging. 2019;76:201. https://doi.org/10.1016/j.neurobiolaging.2019.01.002. · DOI · Paper page
  46. Tan MGK, Lee C, Lee JH, Francis PT, Williams RJ, Ramirez MJ, et al. Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with A beta burden. Neurochem Int. 2014;64:29. https://doi.org/10.1016/j.neuint.2013.10.013. · DOI
  47. Solarski M, Wang HS, Wille H, Schmitt-Ulms G. Somatostatin in Alzheimer's disease: A new Role for an Old Player. Prion. 2018;12:1. https://doi.org/10.1080/19336896.2017.1405207. · DOI · Paper page
  48. Meier S, Bell M, Lyons DN, Ingram A, Chen J, Gensel JC, et al. Identification of Novel Tau Interactions with Endoplasmic Reticulum Proteins in Alzheimer's Disease Brain. J Alzheimers Dis. 2015;48:687. https://doi.org/10.3233/Jad-150298. · DOI · Paper page
  49. Oikari LE, Pandit R, Stewart R, Cuni-Lopez C, Quek H, Sutharsan R, et al. Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. Stem Cell Rep. 2020;14:924. https://doi.org/10.1016/j.stemcr.2020.03.011. · DOI · Paper page
  50. Zheng QY, Huang T, Zhang LS, Zhou Y, Luo H, Xu HX, et al. Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front Aging Neurosci. 2016;8:Artn 303. https://doi.org/10.3389/Fnagi.2016.00303 · DOI · Paper page
  51. Ma PZ, Li YL, Zhang W, Fang FQ, Sun J, Liu MZ, et al. Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease. Curr Alzheimer Res. 2019;16:596. https://doi.org/10.2174/1567205016666190725130134. · DOI
  52. Fernandez-Enright F, Andrews JL. Lingo-1: a novel target in therapy for Alzheimer's disease? Neural Regeneration Research. (2016) 11:88. https://doi.org/10.4103/1673-5374.175048 · DOI
  53. O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553. https://doi.org/10.1038/nri.2016.70. · DOI · Paper page
  54. Frisard M, Ravussin E. Energy metabolism and oxidative stress - Impact on the metabolic syndrome and the aging process. Endocrine. 2006; 29:27. doi: Doi 10.1385/Endo:29:1:27 · DOI · Paper page
  55. Buck MD, O'Sullivan D, Geltink RIK, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016;166:63. https://doi.org/10.1016/j.cell.2016.05.035. · DOI · Paper page
  56. Lee JK, Kim NJ. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease. Molecules. 2017;22:Artn 1287. https://doi.org/10.3390/Molecules22081287 · DOI · Paper page
  57. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 2010;58:561. https://doi.org/10.1016/j.neuropharm.2009.11.010. · DOI · Paper page
  58. Lam D, Enright HA, Cadena J, Peters SKG, Sales AP, Osburn JJ, et al. Tissue-specific extracellular matrix accelerates the formation of neural networks and communities in a neuron-glia co-culture on a multi-electrode array. Scientific Reports. 2019;9:Artn 4159. https://doi.org/10.1038/S41598-019-40128-1 · DOI · Paper page
  59. Zhao LQ, Woody SK, Chhibber A. Estrogen receptor beta in Alzheimer's disease: From mechanisms to therapeutics. Ageing Res Rev. 2015;24:178. https://doi.org/10.1016/j.arr.2015.08.001. · DOI · Paper page
  60. Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer's disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6:22. https://doi.org/10.1186/s40478-018-0515-310.1186/s40478-018-0515-3. · doi:10.1186/s40478-018-0515-310.1186/s40478-018-0515-3
  61. Butt AM, De La Rocha IC, Rivera A. Oligodendroglial Cells in Alzheimer's Disease. Adv Exp Med Biol. 2019;1175:325. https://doi.org/10.1007/978-981-13-9913-8_12. · DOI
  62. Errea O, Rodriguez-Oroz MC. Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease. Mov Disord. 2021;36:83. https://doi.org/10.1002/mds.28393. · DOI
  63. Casella C, Lipp I, Rosser A, Jones DK, Metzler-Baddeley C. A Critical Review of White Matter Changes in Huntington's Disease. Mov Disord. 2020;35:1302. https://doi.org/10.1002/mds.28109. · DOI

Cited by

See all 46

Metadata

Authors
Wang, X.-L., & Li, L.
Venue
BMC Neurology
Published
2021-10-02
Volume
21
Issue
1
Pages
381-381
ISSN
1471-2377 (ISSN-L)
OpenAlex
W3202232284
Cited by
46
References
49
FWCI
3.52
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.